RIBOLIFE-B (06938) announced that its core product, vortosiran (RBD4059), has successfully submitted a Phase 2b Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for the prevention and treatment of venous thromboembolism (VTE). This study is part of the company's broader program of planned Phase 2b trials targeting various thromboembolic cardiovascular indications. VTE remains a leading cause of morbidity and mortality in patients with cardiovascular disease, affecting approximately 10 million people globally each year. A significant proportion of these patients are inadequately treated or discontinue therapy due to the bleeding risks associated with current anticoagulant medications. Vortosiran is a small interfering RNA (siRNA) therapeutic designed for thromboembolic diseases. It works by precisely and durably inhibiting coagulation factor XI (FXI), thereby blocking the FXI-mediated coagulation pathway and suppressing FXI activity. This mechanism aims to provide robust protection against thromboembolism while significantly reducing the risk of bleeding. Compared to existing anticoagulant therapies, vortosiran has the potential to enhance clinical benefits for patients alongside a lower bleeding risk. Vortosiran is the most advanced FXI-targeting nucleic acid drug in global development. As of the date of this announcement, the product has completed a European Phase 2a clinical trial for coronary artery disease (CAD), and its Phase 2b CTA for atrial fibrillation (AF) was submitted to the EMA in April 2026.